|
Getting your Trinity Audio player ready...
|
Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF), a Canadian biotechnology and oral thin film drug delivery company, is drawing increased investor attention following a surge in trading activity alongside continued progress in its QuickStrip™ oral thin film platform.
The stock yesterday closed up 10% in Canada at C$0.11, with approximately 389,000 shares traded—more than 3.5x its 60-day average volume, signaling growing market interest as the Company advances multiple catalysts across nicotine innovation, cannabinoid research, and pharmaceutical delivery technology.
At the center of the story is QuickStrip™, a fast-dissolving oral thin film delivery system designed to enable rapid absorption, precise dosing, and discreet administration of active ingredients. The Company continues to advance human clinical evaluation and infusion of QuickStrip™-delivered compounds, including nicotine and cannabinoids, with a focus on validating bioavailability and pharmacokinetics—key factors for commercial adoption.
Rapid Dose has also strengthened its global intellectual property position with a recently granted patent for its Nicotine Bilayer Oral Film, supporting its strategy within the rapidly growing smoke-free nicotine and nicotine replacement therapy market, projected to reach nearly $39 billion by 2033.
Additional catalysts include ongoing pharmacokinetic (PK) trials, NFL-supported cannabinoid research, expansion into regulated international markets such as Brazil, and enhanced U.S. investor access via its OTCQB listing (RDTCF).
With rising volume, expanding IP protection, and advancing clinical validation, Rapid Dose Therapeutics is emerging as a small-cap biotech stock to watch within the evolving oral thin film drug delivery and nicotine innovation sectors, as investors look ahead to potential commercialization milestones and continued momentum.